Cargando…

Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System

PURPOSE: The plasmid-borne mobilized colistin resistance gene (mcr-1) was discovered in 2015. Subsequently, the rapid horizontal transfer of mcr-1 gene to diverse bacterial species poses a serious threat to public health, which urgently needs the introduction of novel antimicrobial strategies. There...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Peng, Cui, Shiyun, Ma, Zhenbao, Chen, Lin, Li, Xiaoshen, Zhao, Ruonan, Xiong, Wenguang, Zeng, Zhenling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184118/
https://www.ncbi.nlm.nih.gov/pubmed/32368108
http://dx.doi.org/10.2147/IDR.S244885
_version_ 1783526555563065344
author Wan, Peng
Cui, Shiyun
Ma, Zhenbao
Chen, Lin
Li, Xiaoshen
Zhao, Ruonan
Xiong, Wenguang
Zeng, Zhenling
author_facet Wan, Peng
Cui, Shiyun
Ma, Zhenbao
Chen, Lin
Li, Xiaoshen
Zhao, Ruonan
Xiong, Wenguang
Zeng, Zhenling
author_sort Wan, Peng
collection PubMed
description PURPOSE: The plasmid-borne mobilized colistin resistance gene (mcr-1) was discovered in 2015. Subsequently, the rapid horizontal transfer of mcr-1 gene to diverse bacterial species poses a serious threat to public health, which urgently needs the introduction of novel antimicrobial strategies. Therefore, the purpose of this study is to sensitize bacteria to colistin and reduce the propagation of mcr-1 gene by curing mcr-1-harboring plasmid in Escherichia coli (E. coli) using the CRISPR-Cas9 system. METHODS: Two sgRNAs specific to mcr-1 gene were designed and cloned into plasmid pCas9. The recombinant plasmid pCas9-mcr was transformed into E. coli carrying pUC19-mcr-1 or pHNSHP45, separately. The elimination efficiency in strains was evaluated by PCR and quantitative real-time PCR (qPCR). The antimicrobial susceptibility test was performed using the broth microdilution method. RESULTS: In this study, we constructed the high copy number plasmid pUC19-mcr-1 and recombinant plasmid pCas9-m1 or pCas9-m2, which contain 20 nt or 30 nt sgRNA sequences targeted to mcr-1, respectively. PCR and qPCR results showed that mcr-1-harboring plasmids could be efficiently eliminated, and there was no significant correlation between sgRNA lengths and curing efficiency. However, when comparing restructured high copy number plasmid (pUC19-mcr-1) to natural resistance plasmid (pHNSHP45) in eliminating efficiency, we found that the content of plasmid backbone had an influence on efficiency. Furthermore, the conjugation assays verified that the engineered CRISPR-Cas9 system in bacteria or in bacteria genome can protect the recipient from plasmid-borne mcr-1 transfer via conjugation. Additionally, sequence analysis showed that three different types of defects in CRISPR-Cas9 system lead to escape mutants. CONCLUSION: We presented a method that only one plasmid-mediated CRISPR-Cas9 system can be used to efficiently resensitize E. coli to colistin. Moreover, this system provided a great potentiality to counteract the propagation of mcr-1 among bacterial pathogens.
format Online
Article
Text
id pubmed-7184118
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71841182020-05-04 Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System Wan, Peng Cui, Shiyun Ma, Zhenbao Chen, Lin Li, Xiaoshen Zhao, Ruonan Xiong, Wenguang Zeng, Zhenling Infect Drug Resist Original Research PURPOSE: The plasmid-borne mobilized colistin resistance gene (mcr-1) was discovered in 2015. Subsequently, the rapid horizontal transfer of mcr-1 gene to diverse bacterial species poses a serious threat to public health, which urgently needs the introduction of novel antimicrobial strategies. Therefore, the purpose of this study is to sensitize bacteria to colistin and reduce the propagation of mcr-1 gene by curing mcr-1-harboring plasmid in Escherichia coli (E. coli) using the CRISPR-Cas9 system. METHODS: Two sgRNAs specific to mcr-1 gene were designed and cloned into plasmid pCas9. The recombinant plasmid pCas9-mcr was transformed into E. coli carrying pUC19-mcr-1 or pHNSHP45, separately. The elimination efficiency in strains was evaluated by PCR and quantitative real-time PCR (qPCR). The antimicrobial susceptibility test was performed using the broth microdilution method. RESULTS: In this study, we constructed the high copy number plasmid pUC19-mcr-1 and recombinant plasmid pCas9-m1 or pCas9-m2, which contain 20 nt or 30 nt sgRNA sequences targeted to mcr-1, respectively. PCR and qPCR results showed that mcr-1-harboring plasmids could be efficiently eliminated, and there was no significant correlation between sgRNA lengths and curing efficiency. However, when comparing restructured high copy number plasmid (pUC19-mcr-1) to natural resistance plasmid (pHNSHP45) in eliminating efficiency, we found that the content of plasmid backbone had an influence on efficiency. Furthermore, the conjugation assays verified that the engineered CRISPR-Cas9 system in bacteria or in bacteria genome can protect the recipient from plasmid-borne mcr-1 transfer via conjugation. Additionally, sequence analysis showed that three different types of defects in CRISPR-Cas9 system lead to escape mutants. CONCLUSION: We presented a method that only one plasmid-mediated CRISPR-Cas9 system can be used to efficiently resensitize E. coli to colistin. Moreover, this system provided a great potentiality to counteract the propagation of mcr-1 among bacterial pathogens. Dove 2020-04-22 /pmc/articles/PMC7184118/ /pubmed/32368108 http://dx.doi.org/10.2147/IDR.S244885 Text en © 2020 Wan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wan, Peng
Cui, Shiyun
Ma, Zhenbao
Chen, Lin
Li, Xiaoshen
Zhao, Ruonan
Xiong, Wenguang
Zeng, Zhenling
Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System
title Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System
title_full Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System
title_fullStr Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System
title_full_unstemmed Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System
title_short Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System
title_sort reversal of mcr-1-mediated colistin resistance in escherichia coli by crispr-cas9 system
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184118/
https://www.ncbi.nlm.nih.gov/pubmed/32368108
http://dx.doi.org/10.2147/IDR.S244885
work_keys_str_mv AT wanpeng reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system
AT cuishiyun reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system
AT mazhenbao reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system
AT chenlin reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system
AT lixiaoshen reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system
AT zhaoruonan reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system
AT xiongwenguang reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system
AT zengzhenling reversalofmcr1mediatedcolistinresistanceinescherichiacolibycrisprcas9system